CareDx, Inc. (FRA:1K9)
| Market Cap | 757.43M |
| Revenue (ttm) | 305.12M |
| Net Income (ttm) | 60.05M |
| Shares Out | n/a |
| EPS (ttm) | 1.04 |
| PE Ratio | 12.61 |
| Forward PE | 16.81 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 1 |
| Open | 16.26 |
| Previous Close | 15.99 |
| Day's Range | 16.26 - 16.26 |
| 52-Week Range | 9.83 - 24.24 |
| Beta | n/a |
| RSI | 40.12 |
| Earnings Date | Feb 27, 2026 |
About CareDx
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to typ... [Read more]
News
CareDx and 10x Genomics to Launch ImmuneScape Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value health...
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healt...
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinica...
CareDX Has Reached An Inflection Point, But Regulatory Risks Remain (Upgrade)
CareDx Provides Notice of Proposed Derivative Settlement
CareDx, Inc. (Nasdaq: CDNA) today provided notice of proposed settlement of derivative actions and settlement hearing. UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA JEFFREY EDELMAN, JAY...
CareDx Provides Notice of Proposed Derivative Settlement
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today provided notice of proposed settlement of derivative actions and settlement hearing. UNITED STATES DISTRICT COURT NORTHERN DISTRICT...
Crypto.com partners with ERShares and Signal Markets on prediction market intelligence platform
Crypto.com | Derivatives North America (CDNA), a CFTC-registered exchange and clearinghouse affiliated with Crypto.com, has announced a strategic collaboration with … Continue reading The post Crypto....
SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiat...
SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation
CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transp...
CareDx to Participate in Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization ...
CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization ...
CDNA: BTIG Raises Price Target to $25, Maintains Buy Rating | CDNA Stock News
CDNA: BTIG Raises Price Target to $25, Maintains Buy Rating | CDNA Stock News
After-Hours Gainers: VCYT, RIGL, NPCE, CDNA, And FBLG Post Notable Moves Following Q3 Results
(RTTNews) - Several healthcare and biotech names posted strong after-hours gains on Tuesday following the release of third-quarter earnings and updated guidance for the remainder of 2025. The session ...
CareDx Inc (CDNA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance
CareDx Inc (CDNA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance
CareDx raises 2025 revenue guidance to $372M–$376M with robust RCM gains and new product launches
CareDx, Inc (CDNA) Q3 2025 Earnings Call Transcript
CareDx, Inc (CDNA) Q3 2025 Earnings Call November 4, 2025 4:30 PM ESTCompany ParticipantsTina JacobsenJohn Hanna - President, CEO & DirectorNathan Smith...
Q3 2025 CareDx Inc Earnings Call Transcript
Q3 2025 CareDx Inc Earnings Call Transcript
CareDx (CDNA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for CareDx (CDNA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compar...
CareDx Inc (CDNA) Q3 2025 Earnings: EPS of $0. ...
CareDx Inc (CDNA) Q3 2025 Earnings: EPS of $0.03 Beats Estimate, Revenue Surpasses Expectations at $100.1 Million
CareDx Announces Third Quarter 2025 Financial Results
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company — a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthc...
CareDx Announces Third Quarter 2025 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company — a leading precision medicine company focused on the discovery, development and commercialization of clinically...
CareDx Q3 2025 Earnings Preview
CareDx Inc (CDNA) Q3 2025 Earnings Report Preview: What To Expect
CareDx Inc (CDNA) Q3 2025 Earnings Report Preview: What To Expect